Medical Condition News

RSS

Health Canada accepts Cipher Pharmaceuticals' NDS for CIP-TRAMADOL ER

Cipher Pharmaceuticals Inc. today announced that its New Drug Submission (NDS) to Health Canada for CIP-TRAMADOL ER, its extended-release formulation of tramadol, has been accepted for review. The Company expects the review to be completed by early 2011.

26 Mar 2010

Inflamed tissues linked to increased production of protein involved in pain signaling

Using a novel animal model to study craniofacial pain, researchers at Oregon Health & Science University's School of Dentistry have discovered that when tissues are inflamed, the nerve cells carrying pain information from the head to the brain produce in large quantities a protein involved in pain signaling.

26 Mar 2010

Genetic instability in people with Fanconi anemia: New proteins in FA DNA repair pathway may help explain

Identification of two new proteins in the Fanconi anemia DNA repair pathway may help explain genetic instability in people with Fanconi anemia and how otherwise healthy people are susceptible to cancer from environmentally triggered DNA damage.

26 Mar 2010

ARCA biopharma granted patent for methods of treating heart failure patients with bucindolol based on genetic testing

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods of treating heart failure patients with bucindolol based on genetic testing.

26 Mar 2010

Invida to continue commercialization of Actelion's Tracleer for PAH in crucial Asian markets

Invida Group, the leading provider of healthcare brands and services to the Asia Pacific region, today announced that its contract with Swiss biotechnology company, Actelion, has been extended through 2015 to continue commercialization of Tracleer® for the treatment of pulmonary arterial hypertension (PAH) in crucial markets throughout Asia. Actelion signed with Invida initially in 2005, and has extended the contract to market the company’s lead product, Tracleer, in Thailand, Malaysia, Philippines, Vietnam, and Hong Kong

26 Mar 2010

Anxiety may rise again, says Rutgers University dean

Poet W.H Auden dubbed the post-World War II nuclear era the "age of anxiety" and indeed, at the time, anxiety disorders were the most commonly diagnosed mental illnesses. Yet, by the 1990s, American psychiatry was "Listening to Prozac" and instead of obsessing about angst, it focused its attention on depression.

26 Mar 2010

Research Roundup: Middle class health cost burden, disparities and cancer, summary of new health law

The Growing Financial Burden Of Health Care: National And State Trends, 2001-2006 - This paper examines the ratio of total out-of-pocket spending for health care and insurance to total family income, using data from the Medical Expenditure Panel Surveys for 2001-2006.

26 Mar 2010

Collegium Pharmaceutical files IND for second opioid product using DETERx technology

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has filed an Investigational New Drug application for COL-172, a tamper-resistant, extended-release oral opioid formulation intended to treat moderate to severe pain in individuals who require around-the-clock opioid therapy for an extended period of time.

26 Mar 2010

NCMHD announces $3.8M grant for research on minority recruitment in cancer clinical trials

The University of Minnesota Medical School today announced the details of a $3.8 million grant by the National Institutes of Health's National Center on Minority Health and Health Disparities for research focused on minority recruitment and retention in cancer clinical trials.

26 Mar 2010

Presence of protein PARP in tumours may help predict response to chemotherapy

The presence of the protein poly (ADP-ribose) polymerase (PARP) in tumours can help predict their response to chemotherapy, a German scientist will tell the seventh European Breast Cancer Conference (EBCC7) in Barcelona tomorrow (Saturday 27 March). Professor Gunter von Minckwitz, from the German Breast Group Forschungs GmBH, Neu-Isenburg, says that, contrary to current belief that PARP is associated with a limited number of tumours, he and his team found for the first time that PARP expression exists across all breast cancer subtypes, and that such tumours were highly sensitive to chemotherapy.

26 Mar 2010

Medtronic announces enrollment of first European patients in randomized controlled trial of ITB Therapy

Medtronic, Inc. today announced the enrollment of the first European patients in the largest randomized controlled trial to date to investigate the benefits of ITB Therapy(R) (Intrathecal Baclofen) in post-stroke patients affected by spasticity. The announcement comes as the World Congress for Neurorehabilitation is taking place in Vienna, Austria.

26 Mar 2010

U.S. DEA rules prevent nursing home patients in severe pain from receiving needed medication

U.S. Drug Enforcement Administration's rules and procedures are seriously delaying and in some cases preventing nursing home patients from getting the pain medication they need.

26 Mar 2010

Avid, Cardinal Health partner to detect Alzheimer's disease in living patients

Currently, Alzheimer's disease cannot be definitively diagnosed until after death, when a brain autopsy is performed on a patient and evidence of beta-amyloid plaque deposits in the brain – which are a characteristic pathology of the disease – can be found. Accurate diagnosis during life can be challenging, particularly in the early stages of Alzheimer's, when symptoms are mild and non-definitive. However, Avid Radiopharmaceuticals, Inc. and Cardinal Health are working together to change that.

26 Mar 2010

FDA Advisory Committee to review VIVUS' NDA for Qnexa

VIVUS, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration is tentatively scheduled to review the Company's New Drug Application for Qnexa® for the treatment of obesity on July 15, 2010.

26 Mar 2010

BLS acquires AMPAKINE compounds from Cortex Pharmaceuticals

Biovail Corporation today announced that its subsidiary, Biovail Laboratories International SRL, has acquired certain AMPAKINE® compounds, including associated intellectual property, from Cortex Pharmaceuticals, Inc. for use in the field of respiratory depression, a brain-mediated breathing disorder.

26 Mar 2010

Pravastatin benefits elderly carriers of KIF6 gene variant with prior vascular disease

Celera Corporation today announced the publication of data reporting that elderly (over age 70) carriers of the KIF6 gene variant with prior vascular disease received significant benefit from pravastatin (Pravachol®) therapy. Previous research has shown that a variant of the KIF6 gene, a member of the molecular motor protein kinesin family, is associated with up to a 55% increased risk of primary and recurrent coronary heart disease (CHD) events in the placebo arms of the clinical trials, and that this increased risk is virtually eliminated with statin therapy.

26 Mar 2010

Genentech, Biogen Idec file declaratory relief complaint against GSK regarding Arzerra

Genmab A/S announced today that on March 23, 2010 Genentech, Inc. and Biogen Idec, Inc. filed a declaratory relief complaint at the US District Court, Southern District of California against Genmab's collaboration partner GlaxoSmithKline (GSK) for patent infringement under US patent No 7,682,612 based on GSK's manufacture, marketing and sale of Arzerra™ in the United States for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL).

26 Mar 2010

Roche NimbleGen' s microarray technologies help identify genes responsible for CRC

In a recently published study in the journal Genome Research, a team of scientists led by Dr. Shaying Zhao at the University of Georgia have developed a novel cross-species comparative genomics and oncology strategy for cancer driver gene discovery, using microarray technologies from Roche NimbleGen, that differs fundamentally from current approaches which focus on human cancers only.

26 Mar 2010

Bevacizumab/paclitaxel/carboplatin regimen attains gold-standard status for treatment of non-small-cell lung cancer

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018.

26 Mar 2010

Educating African Americans on colorectal cancer screening can reduce death rates

Physician experts from the American College of Gastroenterology raised concern that the majority of African Americans are not aware of the recommendation that they should undergo colorectal cancer screening beginning at age 45—five years before current guidelines generally recommend.

26 Mar 2010

Medical Condition News

Health Canada accepts Cipher Pharmaceuticals' NDS for CIP-TRAMADOL ER

Inflamed tissues linked to increased production of protein involved in pain signaling

Genetic instability in people with Fanconi anemia: New proteins in FA DNA repair pathway may help explain

ARCA biopharma granted patent for methods of treating heart failure patients with bucindolol based on genetic testing

Invida to continue commercialization of Actelion's Tracleer for PAH in crucial Asian markets

Anxiety may rise again, says Rutgers University dean

Research Roundup: Middle class health cost burden, disparities and cancer, summary of new health law

Collegium Pharmaceutical files IND for second opioid product using DETERx technology

NCMHD announces $3.8M grant for research on minority recruitment in cancer clinical trials

Presence of protein PARP in tumours may help predict response to chemotherapy

Medtronic announces enrollment of first European patients in randomized controlled trial of ITB Therapy

U.S. DEA rules prevent nursing home patients in severe pain from receiving needed medication

Avid, Cardinal Health partner to detect Alzheimer's disease in living patients

FDA Advisory Committee to review VIVUS' NDA for Qnexa

BLS acquires AMPAKINE compounds from Cortex Pharmaceuticals

Pravastatin benefits elderly carriers of KIF6 gene variant with prior vascular disease

Genentech, Biogen Idec file declaratory relief complaint against GSK regarding Arzerra

Roche NimbleGen' s microarray technologies help identify genes responsible for CRC

Bevacizumab/paclitaxel/carboplatin regimen attains gold-standard status for treatment of non-small-cell lung cancer

Educating African Americans on colorectal cancer screening can reduce death rates

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News